Seeking Alpha

Street darling Pharmacyclics upgraded at Goldman

  • Goldman is out with some new estimates for Pharmacyclics' (PCYC) Ibrutinib.
  • Analyst Navdeep Singh sees a $5B opportunity in CLL and a $2.5B opportunity in MCL, WM, and DLBCL.
  • Singh's price target is upped to $170 (from $111), representing a 38% premium to Thursday's close.
  • Optimism surrounding Ibrutinib has reached a fever pitch, and some estimates peg the drug's potential as high as $9B.
  • PCYC +6.3% premarket.
Comments (1)
  • Janice214
    , contributor
    Comment (1) | Send Message
     
    I had non hodgkins follicular lymphoma and also am a nurse. I have been following pcyc since it was 6. I have said it will be 150 by Dec. This drug is changing the face of hematological diseases.
    11 Oct 2013, 09:11 AM Reply Like
DJIA (DIA) S&P 500 (SPY)
ETF Tools
Find the right ETFs for your portfolio:
Seeking Alpha's new ETF Hub
ETF Investment Guide:
Table of Contents | One Page Summary
Read about different ETF Asset Classes:
ETF Selector

Next headline on your portfolio:

|